Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 1, 1999, Pages 29-38

  Luo, Feng R ^a   Wyrick, Steven D ^a   Chaney, Stephen G ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Biotransformation products; Neurotoxicity; Ormaplatin; Oxaliplatin; Rat dorsal root ganglia

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; TETRAPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TRANSFORMATION; DRUG UPTAKE; EXPLANT; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NERVE FIBER GROWTH; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL GANGLION;

ANIMALS; BIOTRANSFORMATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GANGLIA, SPINAL; HYDROLYSIS; NERVOUS SYSTEM; ORGANOPLATINUM COMPOUNDS; RATS; RATS, WISTAR;

EID: 0033030078     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050941     Document Type: Article

References (51)

1. Anderson WK, Quagliato DA, Haugwitz RD, Narayanan VL, Wolpert-DeFilippes MK (1986) Synthesis, physical properties, and anti-tumor activity of tetraplatin and related tetrachloro-platinum (IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep 70: 997
2. Apfel SC, Arezzo JC, Lipson L, Kessler JA (1992) Nerve growth factor prevents experimental cisplatin neurotoxicity. Ann Neurol 31: 76
3. Barajon I, Bersani M, Quartu M, Fiacco MD, Cavaletti G, Holst JJ, Tredici G (1996) Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol 138: 93
4. Blisard KS, Rogers S, Alexander S, Harrington D (1992) Neurotoxic effects of platinum compounds in cultured dorsal root ganglion cells. J Exp Pathol 6: 65
5. Burchenal JH, Kalaker K, O'Toole T, Chisholm J (1977) Lack of cross-resistance between certain platinum coordinate compounds in mouse leukemia. Cancer Res 37: 3455
6. Carfagna PF, Poma A, Wyrick SD, Holbrook DJ, Chaney SG (1991) Comparisons of tetra-chloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum (IV) biotransformations in the plasma of Fisher 344 rats at therapeutic and toxic doses. Cancer Chemother Pharmacol 27: 335
7. Cavaletti G, Tredici G, Marmiorlin P, Petruccioli MG, Barajon I, Fabbrica D (1992) Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 84: 364
8. Chaney SG, Wyrick S, Till GK (1990) In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum (IV) (Tetraplatin) in rat plasma. Cancer Res 50: 4539
9. Christian MC (1992) The current status of new platinum analogs. Semin Oncol 19: 720
10. Daley-Yates PY, McBrien DCH (1984) Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and anti-tumor activity of cisplatin. Biochem Pharmacol 33: 3063
11. Daley-Yates PY (1986) The metabolites of platinum anti-tumor drugs and their biological significance. In: McBrien DCH, Slater TF (eds) Biological mechanisms of platinum anti-tumor drug. IRL, Oxford, p 121
12. Engineer MS, Brown NS, Ho DW, Newman RA, Bulter REA (1989) Comparison of the effects of tetraplatin and cisplatin on renal function and gentamycin pharmacology in rats. Toxicology 59: 151
13. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25: 299
14. 4-9 analogue against the toxic effects of cisplatin and taxol on sensory neurons and glial cells in vitro. J Neurosci Res 39: 178
15. Holmes J, Stanko J, Varchenko M, Ding H, Madden V, Bagnell CR, Wyrick SD, Chaney SG (1998) Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wister rat model. Toxicol Sci 46: 342
16. Hayakawa K, Sobue G, Itoh T, Mitsuma T (1994) Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion expiants in vitro. Life Sci 55: 519
17. Kelland LR, Abel G, Mckeage MJ (1993) Preclinical anti-tumor evaluation of bisacetatoammine dichloro(cyclochexylamine)platinum (IV) (JM216): an orally active platinum drug. Cancer Res 53: 2811
18. Kidani Y, Noji M, Tashiro T (1980) Anti-tumor activity of platinum (II) complexes of 1,2-diaminocyclohexane isomers. Jpn Cancer Res 71: 637
19. Kidani Y (1991) Preparative development of antitumor 1,2-cyclohexanediamine platinum complexes. Trends Inorg Chem 1: 107
20. Kido Y, Khokhar AR, Al-Baker S, Siddik ZH (1993) Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Cancer Res 53: 4567
21. Lambert HE, Berr RJ (1985) High-dose cisplatin compared with high-dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. BMJ 290: 889
22. Luo FR, Wyrick SD, Chaney SG (1999) Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Cancer Chemother Pharmacol 44: 19
23. Luo FR, Wyrick SD, Chaney SG (1999) Biotransformations of oxaliplatin in rat blood In vitro. J Biochem Mol Toxicol (in press)
24. Mathe G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, De Vassale S, Chenu E, Bourut C (1989) Oxalato-platinum or l-OPH, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43: 237
25. Mauldin SK, Richard F, Plescia M, Wyrick SD, Sancar A, Chaney SG (1986) High performance liquid Chromatographic separation of platinum complexes containing the 1,2-diaminocyclohexane carrier ligand. Anal Biochem 157: 129
26. Misset JL, Kinadi Y, Gastiburu J (1991) Oxalatoplatinum (l-OHP): experimental and clinical studies. In: Howell SB (ed) Platinum and other metal coordination complexes in cancer chemotherapy. Plenum Press, New York, p 369
27. Mollan JE, Glover DJ, Hogan WM, Furman RE (1988) Cisplatin neuropathy: risk factor, prognosis, and protection by WR-2721. Cancer 61: 2192
28. Mollan JE (1990) Cisplatin neurotoxicity. New Engl J Med 332: 126
29. Muller LJ, Hoop R van der, Moorer-van Delft CM, Gispen WH, Roubos EW (1990) Morphological and electrophysiological study of the effects of cisplatin and ORG 2766 on rat spinal ganglion neurons. Cancer Res 50: 2437
30. New P, Barohn R, O'Rourke T, Seharaseyan J, Mendell JR, Sahenk Z (1993) Neuropathy following ormaplatin administration: human and laboratory studies. Proc Am Soc Clin Oncol 12: 155
31. O'Rourke TJ, Weiss GR, New P, Burris HA, Rodriguez G, Eckhardt J, Hardy J, Kuhn JG, Fields S, Clark GM, Hoff DD von (1994) Phase I clinical trial of ormaplatin (tetraplatin, NCS 363812). Anticancer Drugs 5: 520
32. Ozols RF (1991) Ovarian cancer: new clinical approaches. Cancer Treat Rev 18: 77
33. Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53: 5970
34. Perez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC (1991) Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int J Cancer 48: 265
35. Ribaud P, Kelson DP, Alcok N, Garcia-Giralt E, Dubouch P, Young CC, Muggia FM, Burchenal JH, Mathe G (1980) Preclinical and phase I studies of malonatoplatinum. Recent Results Cancer Res 74: 156
36. Sakata M, Chaney SG, Spriggs DR (1995) Possible correlation between ormaplatin biotransformations and neurotoxicity. Oncol Res 7: 67
37. Schilder RJ, LaCreta FP, Ferez RP, Johnson SW, Brennan JM, Rogstko A, Nash S, Mcaleer C, Hamilton TC, Roby D, Young RC, Ozols RF, O'Dwyer PJ (1994) Phase-I and pharmacokinetic study of ormaplatin (tetraplatin NCS-363812) administered on a day-1 and day-8 schedule. Cancer Res 54: 709
38. Siddik ZH, Newell DR, Boxall FE, Harrap KR (1987) The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36: 1925
39. Siddik ZH, Al-Baker S, Burditt TL, Khokhar AR (1993) Differential anti-tumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes. Cancer Res Clin Oncol 120: 12
40. Siddik ZH, Al-Baker S, Thai G, Khokhar AR (1994) Modulatory effects of axial and equatorial ligands on anti-tumor activities of trans-1R, 2R-diaminocyclohexane platinum (IV) complexes. Anticancer Drug Des 9: 139
41. Smith MA, Smith JH, Litterst CL, Copley MP, Uozumi J, Boyd MR (1988) In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat. Fundam Appl Toxicol 10: 62
42. Tashio T, Kawada Y, Sakurai Y, Kinadi Y (1989) Anti tumor activity of a new platinum complex, oxalato-(trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother 43: 251
43. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC (1984) Cisplatin neuropathy. Clinical, electrophysiological, morphologic, and toxicological studies. Cancer 54: 1269
44. Tomiwa K, Nolan C, Cavanagh JB (1986) The effects of cisplatinum on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol (Berl) 69: 295
45. Tutsch KD, Arzomania RZ, Alberti D, Feierabend C, Robins HL, Spriggs DR (1992) Phase I trial and pharmacokinetic studies of ormaplatin. Proc Am Assoc Cancer Res 33: 536
46. Vijgh WJF van der, Klein I (1986) Protein binding of five platinum compounds. Cancer Chemother Pharmacol 18: 129
47. Hoop RG van der, Veght CJ, Burg MEL van der, Elderson A, Boogerd W, Heimans JJ, Vries EP, Houwelingen JC van, Jennekens FGI, Gispan JG, Neijt JP (1990) Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. New Engl J Med 322: 89
48. Wilkoff LJ, Dulmadge EA, Trader MW, Harrison SD Jr, Griswold DP (1987) Evaluation of trans-tetrachloro-1,2-diaminocyclohexaneplatinum(IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 20: 96
49. Windebank AJ, Blexrud MD (1986) Characteristics of neurite out-growth from rat spinal ganglia: effects of serum and segmentai level. J Neuropathol Exp 45: 683
50. Windebank AJ, Smith SG, Russell JW (1994) The effect of nerve growth factor ciliary neurotrophic factors, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 44: 488
51. Wyrick SD, Chaney SG (1987) Tritiated platinum anti-tumor agents containing the trans (d,l)-1,2-diaminocyclohexane carrier ligand. J Labelled compound Radiopharm 25: 349